Clinical Prediction of Alzheimer Disease Dementia Across the Spectrum of Mild Cognitive Impairment

Harvard University, Cambridge, Massachusetts, United States
Archives of general psychiatry (Impact Factor: 14.48). 12/2007; 64(12):1443-50. DOI: 10.1001/archpsyc.64.12.1443
Source: PubMed


To determine whether clinical assessment methods that grade the severity of impairments within the spectrum of mild cognitive impairment (MCI) can predict clinical course, particularly among very mildly impaired individuals who do not meet formal MCI criteria as implemented in clinical trials.
Community volunteers.
From a longitudinal study of normal (Clinical Dementia Rating [CDR] = 0; n = 77) and mildly impaired (CDR = 0.5; n = 167) participants with 5 or more annual clinical assessments, baseline level of cognitive impairment in daily life was graded using CDR sum of boxes (CDR-SB) and level of cognitive performance impairment was graded using neuropsychological test scores.
Five-year outcome measures included (1) probable Alzheimer disease (AD) diagnosis and (2) clinical "decline" (CDR-SB increase > or = 1.0). Logistic regression models were used to assess the ability of baseline measures to predict outcomes in the full sample and separately in the subjects who did not meet formal MCI criteria as implemented in a multicenter clinical trial (n = 125; "very mild cognitive impairment" [vMCI]).
The presence of both higher CDR-SB and lower verbal memory and executive function at baseline predicted greater likelihood of probable AD and decline. Five-year rates of probable AD and decline in vMCI (20%, AD; 49%, decline) were intermediate between normal participants (0%, AD; 28%, decline) and participants with MCI (41%, AD; 62%, decline). Within vMCI, likelihood of probable AD was predicted by higher CDR-SB and lower executive function.
Even in very mildly impaired individuals who do not meet strict MCI criteria as implemented in clinical trials, the degree of cognitive impairment in daily life and performance on neuropsychological testing predict likelihood of an AD diagnosis within 5 years. The clinical determination of relative severity of impairment along the spectrum of MCI may be valuable for trials of putative disease-modifying compounds, particularly as target populations are broadened to include less impaired individuals.

Download full-text


Available from: Bradford Dickerson, Dec 13, 2013
  • Source
    • "The Clinical Dementia Rating (CDR) scale (Morris, 1993) is widely used in Alzheimer's disease clinical assessment and research trials to grade cognitive impairment and level of daily functioning. Research in Alzheimer's disease has shown that the sole use of performance-based measures, such as those typically used in stroke aphasiology (e.g., Boston Diagnostic Aphasia Examination (BDAE)) (Goodglass, Kaplan, & Barresi, 2000), fails to adequately capture information about symptom severity in daily life, while ratings of symptom severity based on the clinician's judgement may provide complementary information and help in the scoring of disease severity (Dickerson, Sperling, Hyman, Albert, & Blacker, 2007). In PPA clinical care and research programs as well, the use of a structured, semiquantitative instrument that allows the clinician to rate the relative severity of impairment in each language domain based on language assessment and patient and partner interview may provide a more complete clinical picture, rather than solely using information from test performance. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Primary progressive aphasia (PPA) is a devastating neurodegenerative syndrome involving the gradual development of aphasia, slowly impairing the patient’s ability to communicate. Pharmaceutical treatments do not currently exist and intervention often focuses on speech and language behavioural therapies, although further investigation is warranted to determine how best to harness functional benefits. Efforts to develop pharmaceutical and behavioural treatments have been hindered by a lack of standardised methods to monitor disease progression and treatment efficacy.
    Aphasiology 08/2014; 28(8-9):993-1003. DOI:10.1080/02687038.2014.931563 · 1.53 Impact Factor
  • Source
    • "There are currently several means for predicting the progression of MCI, such as structural magnetic resonance imaging (MRI),13,14 functional imaging techniques ([18]F- fluorodeoxyglucose positron emission tomography),15 analysis of the biomarkers in cerebrospinal fluid,16 and the use of molecular imaging.17 "
    [Show abstract] [Hide abstract]
    ABSTRACT: A great amount of research has been developed around the early cognitive impairments that best predict the onset of Alzheimer’s disease (AD). Given that mild cognitive impairment (MCI) is no longer considered to be an intermediate state between normal aging and AD, new paths have been traced to acquire further knowledge about this condition and its subtypes, and to determine which of them have a higher risk of conversion to AD. It is now known that other deficits besides episodic and semantic memory impairments may be present in the early stages of AD, such as visuospatial and executive function deficits. Furthermore, recent investigations have proven that the hippocampus and the medial temporal lobe struc- tures are not only involved in memory functioning, but also in visual processes. These early changes in memory, visual, and executive processes may also be detected with the study of eye movement patterns in pathological conditions like MCI and AD. In the present review, we attempt to explore the existing literature concerning these patterns of oculomotor changes and how these changes are related to the early signs of AD. In particular, we argue that deficits in visual short-term memory, specifically in iconic memory, attention processes, and inhibitory control, may be found through the analysis of eye movement patterns, and we discuss how they might help to predict the progression from MCI to AD. We add that the study of eye movement patterns in these conditions, in combination with neuroimaging techniques and appropriate neuropsychological tasks based on rigorous concepts derived from cognitive psychology, may highlight the early presence of cognitive impairments in the course of the disease.
    Neuropsychiatric Disease and Treatment 07/2014; 10. DOI:10.2147/NDT.S55371 · 1.74 Impact Factor
  • Source
    • "This was explored by controlling for normalized volume of relevant GM or WM structures in the case of significant DTI-CSF partial correlations (i.e., adding left hippocampus volume or left fornix volume to the significant left fornix WM integrityeCSF models). Finally, the functional relevance of significant DTIeCSF associations was explored through partial correlations between FA in that ROI and 2 UDS cognitive test scores of high relevance to preclinical AD states (Logical Memory Delayed and Digit Symbol) (Blacker et al., 2007; Dickerson et al., 2007), as well as a control measure of psychomotor speed (Trails A). To limit the number of comparisons, relationships between other more specific component diffusivity measures (DR/DA/MD) and these cognitive tests were only explored in the presence of significant FA-cognitive score relationships. "
    [Show abstract] [Hide abstract]
    ABSTRACT: We explored whether white matter (WM) integrity in cognitively normal (CN) older adults is associated with cerebrospinal fluid (CSF) markers of Alzheimer's disease pathology. Twenty CN older adults underwent lumbar puncture and magnetic resonance imaging within a few days of each other. Analysis of diffusion tensor imaging data involved a priori region of interest and voxelwise approaches. The region of interest results revealed a positive correlation between CSF measures of amyloid-beta (Aβ42 and Aβ42/p-Tau181) and WM integrity in the fornix, a relationship which persisted after controlling for hippocampal volume and fornix volume. Lower WM integrity in the same portion of the fornix was also associated with reduced performance on the Digit Symbol test. Subsequent exploratory voxelwise analyses indicated a positive correlation between CSF Aβ42/p-Tau181 and WM integrity in bilateral portions of the fornix, superior longitudinal fasciculus, inferior fronto-occipital fasciculus, and in the corpus callosum and left inferior longitudinal fasciculus. Our results link lower WM microstructural integrity in CN older adults with CSF biomarkers of Alzheimer's disease and suggest that this association in the fornix may be independent of volumetric measures.
    Neurobiology of Aging 05/2014; 35(10). DOI:10.1016/j.neurobiolaging.2014.04.030 · 5.01 Impact Factor
Show more